Media.Player

Mouse model for the development of more effective schizophrenia drugs

Summary

Treatments for schizophrenia are currently lacking, even though it affects 1% of the population globally. This technology is a mouse model of the human ZDHHC8 gene. The deletion of this gene is known to be the leading cause of nonfamilial schizophrenia. Genetic variance in this gene causes a defect in neuron structure and brain function that most commonly manifests as schizophrenia. This technology may provide a route towards effective schizophrenia therapies.

Technology Benefits

Causative genetic association with diseaseClear correlation between molecular mechanism and pathological outcomeTech Ventures Reference: IR CU15276

Technology Application

Drug development for schizophrenia medicationTool to study disease mechanism and pathophysiology

Detailed Technology Description

None

*Abstract

None

*Inquiry

Peter GolikovColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu

*IR

CU15276

*Principal Investigator

*Publications

Mukai J, Liu H, Burt RA, Swor D, Lai W-S, Karayiorgou M & Gogos JA. Evidence that the gene encoding ZDHHC8 contributes to the risk of the 22q11-associated schizophrenia. Nature Genetics 36, 725-31 (2004).Mukai J, Dhilla A, Drew LJ, Stark KL, Cao L, MacDermott AB, Karayiorgou M & Gogos JA. Palmitoylation-dependent neurodevelopmental deficits in a mouse model of 22q11 microdeletion. Nature Neuroscience 11, 1302-10 (2008).Mukai J, Tamura M, Fénelon K, Rosen AM, Spellman TJ, Kang R, MacDermott AB, Karayiorgou M, Gordon JA, Gogos JA. Molecular substrates of altered axonal growth and brain connectivity in a mouse model of schizophrenia. Neuron 86, 680-95 (2015).

Country/Region

USA